undefined undefined
NaN.000
NaN.00%
The U.S. FDA has granted Fast Track designation to Compass Therapeutics' (NASDAQ:CMPX) CTX-009 in combination with paclitaxel for previously treated advanced biliary tract cancer. The candidate is cur...
04-26 00:07
Compass Therapeutics (CMPX) has issued an announcement. Compass Therapeutics, I...
04-25 20:12
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
04-16 22:00
Wedbush analyst Robert Driscoll reiterates Compass Therapeutics (NASDAQ:CMPX) with a Outperform and maintains $8 price target.
03-22 21:58
Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on Compass ...
03-21 23:15
We continue to open clinical sites and enroll patients in COMPANION-002, the Phase 2/3 randomized study of CTX-009 (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer (BTC). Consistent with
01-05 21:11
Compass Therapeutics (NASDAQ:CMPX) reported its Q3 earnings results on Thursday...
2023-11-09 20:45
Gainers Helius Medical Technologies, Inc. (NASDAQ: HSDT) rose 65.3% to $12.20 in pre-market trading after gaining around 9% on Friday.
2023-09-05 20:11
What is the target price for Compass Therapeutics (CMPX)?The latest price targe...
2023-08-04 01:24
Gainers Allarity Therapeutics (NASDAQ:ALLR) shares increased by 26.6% to $3.33...
2023-07-31 21:06